Latest From MediciNova Inc.
TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.
The only approved treatment for primary progressive MS is Roche's Ocrevus but there is a possible competitor on the horizon following promising Phase II data which showed that ibudilast slowed brain shrinkage by nearly half.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
In a busy month, MD Anderson also partners with Ipsen on an unspecified cancer drug and licenses poziotinib IP to Spectrum. Using IP from UCLA, Bloom launches with focus on neuroprotective epilepsy therapies.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Hepatic (Liver)
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- North America
- Parent & Subsidiaries
- MediciNova Inc.
- Senior Management
Yuichi Iwaki, MD, PhD, Pres. & CEO
Ryan Selhorn, CPA, CFO
Masatsune Okajima, VP, Head Japan
Kazuko Matsuda, MD, PhD, CMO
Geoffrey O'Brien, JD, MBA, VP
- Contact Info
Phone: (858) 373-1500
4275 Executive Sq.
La Jolla, CA 92037
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.